Molecular stratification of colorectal cancer populations and its use in directing precision medicine
- 4 July 2017
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Precision Medicine and Drug Development
- Vol. 2 (4) , 205-215
Abstract
Introduction: The intrinsic heterogeneity of colorectal cancer (CRC) makes it difficult to determine which patients will benefit from adjuvant or systemic therapy and which patients will not require further treatment beyond surgical resection. This had led to a generalized ‘one size fits all’ approach to therapy. Such heterogeneity also makes it a great challenge to predict which patients might respond to targeted therapies. Precision medical diagnostics now hold promise to address these new challenges. Areas covered: The authors first review various molecular/genomic classification studies of colorectal cancer, including the prognostic role of MSI (microsatellite instability), CIN (chromosomal instability), and driver genes such as KRAS, NRAS, BRAF, PIK3CA and TP53, as well as our recent finding revealing a new prognostic role of APC and partnering mutations with KRAS and TP53. The authors then discuss prediction of treatment response for either adjuvant therapy or systemic targeted therapy (e.g. anti-EGFR therapy) as well as the effect of tumor sidedness. Expert commentary: There is an urgent need for more precise molecular classification to stratify adjuvant therapy and systemic targeted therapy to ultimately facilitate individualized treatments. Sequencing of APC may have clinical utility in the routine staging and potential therapeutic assignment for CRC patients.Keywords
Funding Information
- NIH (U01CA157960 (to TJY))
This publication has 139 references indexed in Scilit:
- Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancerThe Journal of Pathology, 2013
- Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic ValuePLOS Medicine, 2013
- Use of multivariate analysis to suggest a new molecular classification of colorectal cancerThe Journal of Pathology, 2012
- Recurrent R-spondin fusions in colon cancerNature, 2012
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With CetuximabJAMA, 2010
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisThe Lancet Oncology, 2010
- A novel function of adenomatous polyposis coli (APC) in regulating DNA repairCancer Letters, 2008
- Are there two sides to colorectal cancer?International Journal of Cancer, 2002
- Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancerThe Lancet, 2000